

## HR 7032

### Increasing Transparency in Generic Drug Applications Act of 2022

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 9, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 10, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/7032>

### Sponsor

**Name:** Rep. Kuster, Ann M. [D-NH-2]

**Party:** Democratic • **State:** NH • **Chamber:** House

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Schrier, Kim [D-WA-8]	D · WA		Apr 1, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 10, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
117 HR 7667	Related bill	<b>Jun 9, 2022:</b> Received in the Senate.
117 S 4338	Related bill	<b>May 26, 2022:</b> Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

### Summary (as of Mar 9, 2022)

#### Increasing Transparency in Generic Drug Applications Act of 2022

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

### Actions Timeline

- Mar 10, 2022:** Referred to the Subcommittee on Health.
- Mar 9, 2022:** Introduced in House
- Mar 9, 2022:** Referred to the House Committee on Energy and Commerce.